Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

In a clinical trial, the company's weight loss pill resulted in a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medication. On average, participants lost 7.8% to ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

RELATED: Luka Doncic has amazing $5 million hidden gesture in new monster Lakers contract Apparently they have intel on how much the EuroLeague champion actual lost - allegedly 31 pounds.

The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight loss drug disappointed, ...

The S&P 500 slid 0.1% on Thursday, Aug. 7, 2025, as new tariffs took effect, raising import duties on goods from numerous U.S. trading partners.

GLP-1's, which are traditionally diabetes medications, have exploded in popularity since they were approved for weight-loss.

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...